COIOSDeep risk insights through multi-disciplinary research across the globe
man in black coat walking on snow covered ground during daytime
Item refines Peer-reviewed Added

RSV vaccines show positive pooled net benefit in older adults, uncertain for maternal use

Across 11 cost-effectiveness studies, RSV vaccination's pooled net benefit was USD 105 in older adults and USD 6 in infants.

This meta-analysis pooled the incremental net benefit (INB) of marketed RSV vaccines against no vaccination. Of 17 model-based evaluations, all from high-income settings, 11 entered random-effects meta-analyses run separately by population. In older adults the pooled INB was USD 105.05 (95% CI 41.89–168.21). It stayed positive when any one study was left out. For infants, via maternal vaccination, it was USD 5.81 (95% CI −35.44 to 47.07), sensitive to study exclusion. Heterogeneity was high (I² 93.2% and 89.4%), and no study came from low- or middle-income countries.

Why it is interesting: Pooling net benefit rather than cost-effectiveness ratios lets economic evaluations be combined on one monetary scale. Among older adults, strategies targeting older ages or higher-risk groups gave higher net benefit than broad age-based programmes.

Source
Infectious Diseases of Poverty, 14 November 2026
DOI
10.1186/s40249-026-01520-y
Full text
Open copy (open-access copy, PubMed Central)
Type
Peer-reviewed article
Design
Systematic review and random-effects meta-analysis of incremental net benefit from 17 post-marketing RSV vaccine economic evaluations (11 in primary meta-analysis), searched to November 2025
Verdict
Refines prior evidence
Driver
Value in health
Driver
Infection and pandemics

Other drivers in Data, models and systems